Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 82

1.

Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion.

Paczulla AM, Rothfelder K, Raffel S, Konantz M, Steinbacher J, Wang H, Tandler C, Mbarga M, Schaefer T, Falcone M, Nievergall E, Dörfel D, Hanns P, Passweg JR, Lutz C, Schwaller J, Zeiser R, Blazar BR, Caligiuri MA, Dirnhofer S, Lundberg P, Kanz L, Quintanilla-Martinez L, Steinle A, Trumpp A, Salih HR, Lengerke C.

Nature. 2019 Jul 17. doi: 10.1038/s41586-019-1410-1. [Epub ahead of print]

PMID:
31316209
2.

Dual roles of EZH2 in acute myeloid leukemia.

Skoda RC, Schwaller J.

J Exp Med. 2019 Apr 1;216(4):725-727. doi: 10.1084/jem.20190250. Epub 2019 Mar 19.

PMID:
30890555
3.

Murine Models of Acute Myeloid Leukaemia.

Almosailleakh M, Schwaller J.

Int J Mol Sci. 2019 Jan 21;20(2). pii: E453. doi: 10.3390/ijms20020453. Review.

4.

Novel insights into the role of aberrantly expressed MNX1 (HLXB9) in infant acute myeloid leukemia.

Schwaller J.

Haematologica. 2019 Jan;104(1):1-3. doi: 10.3324/haematol.2018.205971. No abstract available.

5.

Dasatinib and navitoclax act synergistically to target NUP98-NSD1+/FLT3-ITD+ acute myeloid leukemia.

Kivioja JL, Thanasopoulou A, Kumar A, Kontro M, Yadav B, Majumder MM, Javarappa KK, Eldfors S, Schwaller J, Porkka K, Heckman CA.

Leukemia. 2019 Jun;33(6):1360-1372. doi: 10.1038/s41375-018-0327-2. Epub 2018 Dec 19.

PMID:
30568173
6.

Aggressive leukemia driven by MLL-AF9.

Stavropoulou V, Peters AHFM, Schwaller J.

Mol Cell Oncol. 2017 Oct 23;5(3):e1241854. doi: 10.1080/23723556.2016.1241854. eCollection 2018.

7.

Normal and pathological erythropoiesis in adults: from gene regulation to targeted treatment concepts.

Valent P, Büsche G, Theurl I, Uras IZ, Germing U, Stauder R, Sotlar K, Füreder W, Bettelheim P, Pfeilstöcker M, Oberbauer R, Sperr WR, Geissler K, Schwaller J, Moriggl R, Béné MC, Jäger U, Horny HP, Hermine O.

Haematologica. 2018 Oct;103(10):1593-1603. doi: 10.3324/haematol.2018.192518. Epub 2018 Aug 3. Review.

8.

Targeting multiple nodes of MLL complexes to improve leukemia therapy.

Dafflon C, Tiedt R, Schwaller J.

Oncotarget. 2017 Oct 7;8(53):90614-90615. doi: 10.18632/oncotarget.21598. eCollection 2017 Oct 31. No abstract available.

9.

LEDGF/p75 is dispensable for hematopoiesis but essential for MLL-rearranged leukemogenesis.

El Ashkar S, Schwaller J, Pieters T, Goossens S, Demeulemeester J, Christ F, Van Belle S, Juge S, Boeckx N, Engelman A, Van Vlierberghe P, Debyser Z, De Rijck J.

Blood. 2018 Jan 4;131(1):95-107. doi: 10.1182/blood-2017-05-786962. Epub 2017 Oct 30.

10.

ETO2-GLIS2 Hijacks Transcriptional Complexes to Drive Cellular Identity and Self-Renewal in Pediatric Acute Megakaryoblastic Leukemia.

Thirant C, Ignacimouttou C, Lopez CK, Diop M, Le Mouël L, Thiollier C, Siret A, Dessen P, Aid Z, Rivière J, Rameau P, Lefebvre C, Khaled M, Leverger G, Ballerini P, Petit A, Raslova H, Carmichael CL, Kile BT, Soler E, Crispino JD, Wichmann C, Pflumio F, Schwaller J, Vainchenker W, Lobry C, Droin N, Bernard OA, Malinge S, Mercher T.

Cancer Cell. 2017 Mar 13;31(3):452-465. doi: 10.1016/j.ccell.2017.02.006.

11.

Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia.

Dafflon C, Craig VJ, Méreau H, Gräsel J, Schacher Engstler B, Hoffman G, Nigsch F, Gaulis S, Barys L, Ito M, Aguadé-Gorgorió J, Bornhauser B, Bourquin JP, Proske A, Stork-Fux C, Murakami M, Sellers WR, Hofmann F, Schwaller J, Tiedt R.

Leukemia. 2017 Jun;31(6):1269-1277. doi: 10.1038/leu.2016.327. Epub 2016 Nov 14.

PMID:
27840424
12.

Promiscuous targeting of bromodomains by bromosporine identifies BET proteins as master regulators of primary transcription response in leukemia.

Picaud S, Leonards K, Lambert JP, Dovey O, Wells C, Fedorov O, Monteiro O, Fujisawa T, Wang CY, Lingard H, Tallant C, Nikbin N, Guetzoyan L, Ingham R, Ley SV, Brennan P, Muller S, Samsonova A, Gingras AC, Schwaller J, Vassiliou G, Knapp S, Filippakopoulos P.

Sci Adv. 2016 Oct 12;2(10):e1600760. eCollection 2016 Oct.

13.

MLL-AF9 Expression in Hematopoietic Stem Cells Drives a Highly Invasive AML Expressing EMT-Related Genes Linked to Poor Outcome.

Stavropoulou V, Kaspar S, Brault L, Sanders MA, Juge S, Morettini S, Tzankov A, Iacovino M, Lau IJ, Milne TA, Royo H, Kyba M, Valk PJM, Peters AHFM, Schwaller J.

Cancer Cell. 2016 Jul 11;30(1):43-58. doi: 10.1016/j.ccell.2016.05.011. Epub 2016 Jun 23.

14.

Expression of Leukemia-Associated Nup98 Fusion Proteins Generates an Aberrant Nuclear Envelope Phenotype.

Fahrenkrog B, Martinelli V, Nilles N, Fruhmann G, Chatel G, Juge S, Sauder U, Di Giacomo D, Mecucci C, Schwaller J.

PLoS One. 2016 Mar 31;11(3):e0152321. doi: 10.1371/journal.pone.0152321. eCollection 2016.

15.

Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy.

Picaud S, Fedorov O, Thanasopoulou A, Leonards K, Jones K, Meier J, Olzscha H, Monteiro O, Martin S, Philpott M, Tumber A, Filippakopoulos P, Yapp C, Wells C, Che KH, Bannister A, Robson S, Kumar U, Parr N, Lee K, Lugo D, Jeffrey P, Taylor S, Vecellio ML, Bountra C, Brennan PE, O'Mahony A, Velichko S, Müller S, Hay D, Daniels DL, Urh M, La Thangue NB, Kouzarides T, Prinjha R, Schwaller J, Knapp S.

Cancer Res. 2015 Dec 1;75(23):5106-5119. doi: 10.1158/0008-5472.CAN-15-0236. Epub 2015 Nov 9.

16.

Critical role of retinoid/rexinoid signaling in mediating transformation and therapeutic response of NUP98-RARG leukemia.

Qiu JJ, Zeisig BB, Li S, Liu W, Chu H, Song Y, Giordano A, Schwaller J, Gronemeyer H, Dong S, So CW.

Leukemia. 2015 May;29(5):1153-62. doi: 10.1038/leu.2014.334. Epub 2014 Dec 16.

PMID:
25510432
17.

Estrogen signaling selectively induces apoptosis of hematopoietic progenitors and myeloid neoplasms without harming steady-state hematopoiesis.

Sánchez-Aguilera A, Arranz L, Martín-Pérez D, García-García A, Stavropoulou V, Kubovcakova L, Isern J, Martín-Salamanca S, Langa X, Skoda RC, Schwaller J, Méndez-Ferrer S.

Cell Stem Cell. 2014 Dec 4;15(6):791-804. doi: 10.1016/j.stem.2014.11.002.

18.

Validation and structural characterization of the LEDGF/p75-MLL interface as a new target for the treatment of MLL-dependent leukemia.

Cermáková K, Tesina P, Demeulemeester J, El Ashkar S, Méreau H, Schwaller J, Rezáčová P, Veverka V, De Rijck J.

Cancer Res. 2014 Sep 15;74(18):5139-51. doi: 10.1158/0008-5472.CAN-13-3602. Epub 2014 Jul 31.

19.

Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms.

Arranz L, Sánchez-Aguilera A, Martín-Pérez D, Isern J, Langa X, Tzankov A, Lundberg P, Muntión S, Tzeng YS, Lai DM, Schwaller J, Skoda RC, Méndez-Ferrer S.

Nature. 2014 Aug 7;512(7512):78-81. doi: 10.1038/nature13383. Epub 2014 Jun 22.

PMID:
25043017
20.

Potent co-operation between the NUP98-NSD1 fusion and the FLT3-ITD mutation in acute myeloid leukemia induction.

Thanasopoulou A, Tzankov A, Schwaller J.

Haematologica. 2014 Sep;99(9):1465-71. doi: 10.3324/haematol.2013.100917. Epub 2014 Jun 20.

21.

PIM kinases are essential for chronic lymphocytic leukemia cell survival (PIM2/3) and CXCR4-mediated microenvironmental interactions (PIM1).

Decker S, Finter J, Forde AJ, Kissel S, Schwaller J, Mack TS, Kuhn A, Gray N, Follo M, Jumaa H, Burger M, Zirlik K, Pfeifer D, Miduturu CV, Eibel H, Veelken H, Dierks C.

Mol Cancer Ther. 2014 May;13(5):1231-45. doi: 10.1158/1535-7163.MCT-13-0575-T. Epub 2014 Mar 21.

22.

CXCR4-SERINE339 regulates cellular adhesion, retention and mobilization, and is a marker for poor prognosis in acute myeloid leukemia.

Brault L, Rovó A, Decker S, Dierks C, Tzankov A, Schwaller J.

Leukemia. 2014 Mar;28(3):566-76. doi: 10.1038/leu.2013.201. Epub 2013 Jul 2.

PMID:
23817178
23.

Trithorax and polycomb cooperation in MLL fusion acute leukemia.

Méreau H, Schwaller J.

Haematologica. 2013 Jun;98(6):825-7. doi: 10.3324/haematol.2013.084301. No abstract available.

24.

PFI-1, a highly selective protein interaction inhibitor, targeting BET Bromodomains.

Picaud S, Da Costa D, Thanasopoulou A, Filippakopoulos P, Fish PV, Philpott M, Fedorov O, Brennan P, Bunnage ME, Owen DR, Bradner JE, Taniere P, O'Sullivan B, Müller S, Schwaller J, Stankovic T, Knapp S.

Cancer Res. 2013 Jun 1;73(11):3336-46. doi: 10.1158/0008-5472.CAN-12-3292. Epub 2013 Apr 10.

25.

Impairing MLL-fusion gene-mediated transformation by dissecting critical interactions with the lens epithelium-derived growth factor (LEDGF/p75).

Méreau H, De Rijck J, Cermáková K, Kutz A, Juge S, Demeulemeester J, Gijsbers R, Christ F, Debyser Z, Schwaller J.

Leukemia. 2013 Jun;27(6):1245-53. doi: 10.1038/leu.2013.10. Epub 2013 Jan 15.

PMID:
23318960
26.

Modeling ETV6-JAK2-induced leukemia: insights from the zebrafish.

Schwaller J.

Haematologica. 2012 Dec;97(12):1783-5. doi: 10.3324/haematol.2012.080754. No abstract available.

27.

Loss of pim1 imposes a hyperadhesive phenotype on endothelial cells.

Walpen T, Peier M, Haas E, Kalus I, Schwaller J, Battegay E, Humar R.

Cell Physiol Biochem. 2012;30(4):1083-96. doi: 10.1159/000341484. Epub 2012 Sep 24.

28.

Nuclear PIM1 confers resistance to rapamycin-impaired endothelial proliferation.

Walpen T, Kalus I, Schwaller J, Peier MA, Battegay EJ, Humar R.

Biochem Biophys Res Commun. 2012 Dec 7;429(1-2):24-30. doi: 10.1016/j.bbrc.2012.10.106. Epub 2012 Nov 3.

PMID:
23131564
29.

PIM kinases are progression markers and emerging therapeutic targets in diffuse large B-cell lymphoma.

Brault L, Menter T, Obermann EC, Knapp S, Thommen S, Schwaller J, Tzankov A.

Br J Cancer. 2012 Jul 24;107(3):491-500. doi: 10.1038/bjc.2012.272. Epub 2012 Jun 21.

30.

Loss of CCDC6 affects cell cycle through impaired intra-S-phase checkpoint control.

Thanasopoulou A, Stravopodis DJ, Dimas KS, Schwaller J, Anastasiadou E.

PLoS One. 2012;7(2):e31007. doi: 10.1371/journal.pone.0031007. Epub 2012 Feb 17.

31.

7,8-dichloro-1-oxo-β-carbolines as a versatile scaffold for the development of potent and selective kinase inhibitors with unusual binding modes.

Huber K, Brault L, Fedorov O, Gasser C, Filippakopoulos P, Bullock AN, Fabbro D, Trappe J, Schwaller J, Knapp S, Bracher F.

J Med Chem. 2012 Jan 12;55(1):403-13. doi: 10.1021/jm201286z. Epub 2012 Jan 3.

32.

High-throughput kinase profiling: a more efficient approach toward the discovery of new kinase inhibitors.

Miduturu CV, Deng X, Kwiatkowski N, Yang W, Brault L, Filippakopoulos P, Chung E, Yang Q, Schwaller J, Knapp S, King RW, Lee JD, Herrgard S, Zarrinkar P, Gray NS.

Chem Biol. 2011 Jul 29;18(7):868-79. doi: 10.1016/j.chembiol.2011.05.010.

33.

HiJAKing the methylosome in myeloproliferative disorders.

Skoda RC, Schwaller J.

Cancer Cell. 2011 Feb 15;19(2):161-3. doi: 10.1016/j.ccr.2011.01.046.

34.

Epigenetic mechanisms in acute myeloid leukemia.

Peters AH, Schwaller J.

Prog Drug Res. 2011;67:197-219. Review.

PMID:
21141731
35.

Insights into molecular pathways for targeted therapeutics in acute leukemia.

Stavropoulou V, Brault L, Schwaller J.

Swiss Med Wkly. 2010 Sep 9;140:w13068. doi: 10.4414/smw.2010.13068. eCollection 2010. Review.

PMID:
20853191
36.

PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers.

Brault L, Gasser C, Bracher F, Huber K, Knapp S, Schwaller J.

Haematologica. 2010 Jun;95(6):1004-15. doi: 10.3324/haematol.2009.017079. Epub 2010 Feb 9. Review.

37.

Functional characterization of high levels of meningioma 1 as collaborating oncogene in acute leukemia.

Liu T, Jankovic D, Brault L, Ehret S, Baty F, Stavropoulou V, Rossi V, Biondi A, Schwaller J.

Leukemia. 2010 Mar;24(3):601-12. doi: 10.1038/leu.2009.272. Epub 2010 Jan 14.

PMID:
20072157
38.

Dissection of PIM serine/threonine kinases in FLT3-ITD-induced leukemogenesis reveals PIM1 as regulator of CXCL12-CXCR4-mediated homing and migration.

Grundler R, Brault L, Gasser C, Bullock AN, Dechow T, Woetzel S, Pogacic V, Villa A, Ehret S, Berridge G, Spoo A, Dierks C, Biondi A, Knapp S, Duyster J, Schwaller J.

J Exp Med. 2009 Aug 31;206(9):1957-70. doi: 10.1084/jem.20082074. Epub 2009 Aug 17.

39.

Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression.

Mumprecht S, Schürch C, Schwaller J, Solenthaler M, Ochsenbein AF.

Blood. 2009 Aug 20;114(8):1528-36. doi: 10.1182/blood-2008-09-179697. Epub 2009 May 6.

40.

Recurrent numerical aberrations of JAK2 and deregulation of the JAK2-STAT cascade in lymphomas.

Meier C, Hoeller S, Bourgau C, Hirschmann P, Schwaller J, Went P, Pileri SA, Reiter A, Dirnhofer S, Tzankov A.

Mod Pathol. 2009 Mar;22(3):476-87. doi: 10.1038/modpathol.2008.207. Epub 2009 Jan 9.

41.

Role of the tumor necrosis factor ligand APRIL in Hodgkin's lymphoma: a retrospective study including 107 cases.

Went P, Tzankov A, Schwaller J, Passweg J, Roosnek E, Huard B.

Exp Hematol. 2008 May;36(5):533-4. doi: 10.1016/j.exphem.2007.12.017. No abstract available.

PMID:
18439487
42.

Leukemogenic mechanisms and targets of a NUP98/HHEX fusion in acute myeloid leukemia.

Jankovic D, Gorello P, Liu T, Ehret S, La Starza R, Desjobert C, Baty F, Brutsche M, Jayaraman PS, Santoro A, Mecucci C, Schwaller J.

Blood. 2008 Jun 15;111(12):5672-82. doi: 10.1182/blood-2007-09-108175. Epub 2008 Apr 3.

43.

Prostate-specific membrane antigen expression is a potential prognostic marker in endometrial adenocarcinoma.

Mhawech-Fauceglia P, Smiraglia DJ, Bshara W, Andrews C, Schwaller J, South S, Higgs D, Lele S, Herrmann F, Odunsi K.

Cancer Epidemiol Biomarkers Prev. 2008 Mar;17(3):571-7. doi: 10.1158/1055-9965.EPI-07-0511.

44.

Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice.

Tiedt R, Hao-Shen H, Sobas MA, Looser R, Dirnhofer S, Schwaller J, Skoda RC.

Blood. 2008 Apr 15;111(8):3931-40. Epub 2007 Dec 26.

45.

A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.

Fedorov O, Marsden B, Pogacic V, Rellos P, Müller S, Bullock AN, Schwaller J, Sundström M, Knapp S.

Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8. Epub 2007 Dec 11.

46.

Structural analysis identifies imidazo[1,2-b]pyridazines as PIM kinase inhibitors with in vitro antileukemic activity.

Pogacic V, Bullock AN, Fedorov O, Filippakopoulos P, Gasser C, Biondi A, Meyer-Monard S, Knapp S, Schwaller J.

Cancer Res. 2007 Jul 15;67(14):6916-24.

47.

Bcl10 controls TCR- and FcgammaR-induced actin polymerization.

Rueda D, Gaide O, Ho L, Lewkowicz E, Niedergang F, Hailfinger S, Rebeaud F, Guzzardi M, Conne B, Thelen M, Delon J, Ferch U, Mak TW, Ruland J, Schwaller J, Thome M.

J Immunol. 2007 Apr 1;178(7):4373-84.

48.

Paracrine promotion of tumor development by the TNF ligand APRIL in Hodgkin's Disease.

Schwaller J, Went P, Matthes T, Dirnhofer S, Donze O, Mhawech-Fauceglia P, Myit S, Huard B.

Leukemia. 2007 Jun;21(6):1324-7. Epub 2007 Feb 22. No abstract available.

PMID:
17315017
49.

Neutrophil-derived APRIL concentrated in tumor lesions by proteoglycans correlates with human B-cell lymphoma aggressiveness.

Schwaller J, Schneider P, Mhawech-Fauceglia P, McKee T, Myit S, Matthes T, Tschopp J, Donze O, Le Gal FA, Huard B.

Blood. 2007 Jan 1;109(1):331-8. Erratum in: Blood. 2007 Sep 1;110(5):1474.

50.

The source of APRIL up-regulation in human solid tumor lesions.

Mhawech-Fauceglia P, Kaya G, Sauter G, McKee T, Donze O, Schwaller J, Huard B.

J Leukoc Biol. 2006 Oct;80(4):697-704. Epub 2006 Jun 22.

PMID:
16793914

Supplemental Content

Loading ...
Support Center